More articles from Volume 33, Issue 3, 2017
Massive Benign Lingual Tonsil Hyperplasia and Tracheostomy
Do women know what is postpartum depression?
Influence and importance of diabetes: the five-year outcomes in patients who underwent percutaneous coronary intervention
The significance of 4D CT simulation inprecise definition of target volumen lung carcinoma intensity modulated radiation therapy treatment
Myocardial infarction at the patient with parathyroid adenoma
Article views
Presepsin u akutnim i hroničnim poremećajima bubrežne funkcije
,
Zoran Gluvić
,
Bojan Mitrović
,
Andrijana Kulić
,
Ana Strugar
Vesna Libek
Published: 01.12.2016.
Biochemistry
Volume 33, Issue 3 (2017)
pp. 1571-1573;
Abstract
References
1.
Giavarina D, Carta M. Determination of reference interval for presepsin, an early marker for sepsis. Biochemia Medica. :64–8.
2.
Masson S, Caironi P, Fanizza C, Thomae R, Bernasconi R, Noto A, et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Medicine. 2015;41(1):12–20.
3.
Nagata T, Yasuda Y, Ando M, Abe T, Katsuno T, Kato S, et al. Clinical Impact of Kidney Function on Presepsin Levels. PLOS ONE. 10(6):e0129159.
4.
Chenevier-Gobeaux C, Trabattoni E, Roelens M, Borderie D, Claessens YE. Presepsin (sCD14-ST) in emergency department: The need for adapted threshold values? Clinica Chimica Acta. 2014;427:34–6.
5.
Kotera A, Sagishima K, Tashiro T, Niimori D, Kamohara H, Kinoshita Y. A validation of presepsin levels in kidney dysfunction patients: four case reports. Journal of Intensive Care. 2014;2(1).
6.
Honore PM, Jacobs R, Hendrickx I, De Waele E, Van Gorp V, Spapen HD. Presepsin and sepsis-induced acute kidney injury treated with continuous renal replacement therapy: will another promising biomarker bite the dust? Critical Care. 19(1).
7.
Nakamura Y, Ishikura H, Nishida T, Kawano Y, Yuge R, Ichiki R, et al. Usefulness of presepsin in the diagnosis of sepsis in patients with or without acute kidney injury. BMC Anesthesiology. 2014;14(1).
8.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care. 8(4).
9.
Claessens YE, Trabattoni E, Grabar S, Quinquis L, Der Sahakian G, Anselmo M, et al. Plasmatic presepsin (sCD14-ST) concentrations in acute pyelonephritis in adult patients. Clinica Chimica Acta. 2017;464:182–8.
10.
Wu CC, Lan HM, Han ST, Chaou CH, Yeh CF, Liu SH, et al. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis. Annals of Intensive Care. 2017;7(1).
11.
Liu Y, Hou J huan, Li Q, Chen K jun, Wang SN, Wang J min. Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis. SpringerPlus. 2016;5(1).
12.
Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Critical Care. 17(4).
13.
Zanoni I, Granucci F. Role of CD14 in host protection against infections and in metabolism regulation. Frontiers in Cellular and Infection Microbiology. 3.
14.
Zheng Z, Jiang L, Ye L, Gao Y, Tang L, Zhang M. The accuracy of presepsin for the diagnosis of sepsis from SIRS: a systematic review and meta-analysis. Annals of Intensive Care. 2015;5(1).
15.
Jacobs L, Wong HR. Emerging infection and sepsis biomarkers: will they change current therapies? Expert Review of Anti-infective Therapy. 2016;14(10):929–41.
16.
Shozushima T, Takahashi G, Matsumoto N, Kojika M, Endo S, Okamura Y. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. Journal of Infection and Chemotherapy. 2011;17(6):764–9.
17.
Volanakis J. Human C-reactive protein: expression, structure, and function. Molecular Immunology. 2001;38(2–3):189–97.
18.
Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clinica Chimica Acta. 2011;412(23–24):2157–61.
19.
Chenevier-Gobeaux C, Bardet V, Poupet H, Poyart C, Borderie D, Claessens YE. Presepsin (sCD14-ST) secretion and kinetics by peripheral blood mononuclear cells and monocytic THP-1 cell line. Annales de biologie clinique. 2016;74(1):93–7.
20.
Zou Q, Wen W, Zhang X chao. Presepsin as a novel sepsis biomarker. World Journal of Emergency Medicine. 2014;5(1):16.
21.
Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. The Journal of Maternal-Fetal & Neonatal Medicine. 2011;24(sup2):12–4.
22.
Zhang J, Hu ZD, Song J, Shao J. Diagnostic Value of Presepsin for Sepsis. Medicine. 2015;94(47):e2158.
23.
Meuleman P, Steyaert S, Libbrecht L, Couvent S, Van Houtte F, Clinckspoor F, et al. Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection. Clinica Chimica Acta. 2006;366(1–2):156–62.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
